Caligan Partners LP Has $25.76 Million Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Caligan Partners LP raised its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 12.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 579,717 shares of the biopharmaceutical company's stock after purchasing an additional 65,006 shares during the quarter. Agios Pharmaceuticals accounts for about 8.2% of Caligan Partners LP's holdings, making the stock its 6th biggest holding. Caligan Partners LP owned about 1.02% of Agios Pharmaceuticals worth $25,757,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in AGIO. Caxton Associates LP grew its stake in shares of Agios Pharmaceuticals by 0.7% in the second quarter. Caxton Associates LP now owns 37,453 shares of the biopharmaceutical company's stock worth $1,615,000 after purchasing an additional 264 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Agios Pharmaceuticals by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company's stock valued at $94,000 after buying an additional 363 shares during the last quarter. CANADA LIFE ASSURANCE Co increased its stake in shares of Agios Pharmaceuticals by 1.8% in the first quarter. CANADA LIFE ASSURANCE Co now owns 31,144 shares of the biopharmaceutical company's stock valued at $911,000 after buying an additional 540 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Agios Pharmaceuticals by 6.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company's stock worth $539,000 after acquiring an additional 688 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new position in shares of Agios Pharmaceuticals in the second quarter worth approximately $37,000.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on AGIO shares. Scotiabank lifted their target price on shares of Agios Pharmaceuticals from $51.00 to $53.00 and gave the stock a "sector outperform" rating in a research note on Friday, November 1st. Leerink Partnrs lowered Agios Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, September 27th. Royal Bank of Canada restated an "outperform" rating and set a $55.00 target price on shares of Agios Pharmaceuticals in a research report on Friday, November 1st. Leerink Partners downgraded Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and lowered their target price for the stock from $60.00 to $56.00 in a report on Friday, September 27th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Agios Pharmaceuticals has a consensus rating of "Hold" and a consensus price target of $52.33.

Insider Activity at Agios Pharmaceuticals

In related news, CFO Cecilia Jones sold 2,542 shares of the firm's stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the transaction, the chief financial officer now owns 20,158 shares of the company's stock, valued at approximately $988,346.74. This trade represents a 11.20 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.93% of the stock is currently owned by insiders.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ AGIO traded up $0.73 during midday trading on Friday, hitting $59.39. 237,613 shares of the stock traded hands, compared to its average volume of 729,884. Agios Pharmaceuticals, Inc. has a one year low of $20.96 and a one year high of $62.58. The business has a 50 day moving average price of $48.68 and a two-hundred day moving average price of $45.49. The company has a market cap of $3.39 billion, a PE ratio of 5.23 and a beta of 0.75.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.